GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings

Core Insights - GoodRx has announced the availability of Repatha® (evolocumab) at a significantly reduced cash price, making it more accessible to patients [1] - The new price for Repatha is set at $239, which represents a nearly 60% discount off the retail pharmacy list price [1] Company Overview - GoodRx is positioned as the leading platform for medication savings in the U.S., focusing on improving affordability in healthcare [1] Industry Impact - The introduction of a lower cash price for Repatha highlights the ongoing challenges of affordability in the healthcare system, where access is often dictated by cost [1]